February 17, 2012
A number of sodium-glucose cotransporter-2 (SGLT-2) inhibitors developed as next-generation oral diabetes treatments are in the final development stage. Multiple companies aim to file applications in Japan in 2013, and products will be launched as early as 2014. Since the...read more